October 22, 2025

Abdi İbrahim Expands Its Biotechnology Portfolio With a New Ophthalmology Product

Abdi İbrahim, the uninterrupted leader of the Turkish pharmaceutical industry for 23 years, continues to offer innovative solutions that improve treatment access for patients experiencing vision loss. The company aims to enhance patients’ quality of life by introducing Türkiye’s first biosimilar drug in the field of ophthalmology.

By expanding its biotechnology-focused investments, Abdi İbrahim is strengthening its position in ophthalmology through cutting-edge therapeutic solutions.

Abdi İbrahim CEO Dr. Süha Taşpolatoğlu shared the following remarks on this important development: “We have taken a significant step toward improving Turkish patients’ access to high-quality biological products. By combining our expertise in ophthalmology with biological products approved in Europe and the United States, we aim to facilitate access to treatments for serious eye diseases such as age-related macular degeneration (AMD). This development not only reinforces our pioneering role in biotechnology and our patient-centered approach but also stands as a strong testament to our commitment to implementing new therapeutic solutions in critical areas such as ophthalmology and to our contribution to the advancement of the Turkish pharmaceutical industry.”

According to data from September 2025, the market size for biotechnological products in the ophthalmology segment in Türkiye is approximately USD 53 million. The strong demand for biotechnological drugs in the country continues to accelerate the adoption of innovative solutions in this field.

Internationally Approved Solutions

The treatment provides effective solutions for serious eye diseases such as age-related macular degeneration (AMD), diabetic macular edema (DME), retinal vein occlusion, and myopic choroidal neovascularization.

* IQVIA Turkey Pharmaceutical National Index 2025 MAT